Inflammasome genetic variants are associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes.
Brazil
CARD Signaling Adaptor Proteins
Genetic Predisposition to Disease
Genotype
HIV Infections
/ complications
HIV-1
Humans
Immune Reconstitution Inflammatory Syndrome
/ complications
Inflammasomes
/ genetics
Interleukin-18
/ genetics
Interleukin-33
/ genetics
Interleukin-6
/ genetics
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
Neoplasm Proteins
/ genetics
Polymorphism, Single Nucleotide
Tuberculosis
HIV-1
TB-HIV/IRIS
inflammasome Single Nucleotide Polymorphism (SNP)
proinflammatory cytokines
tuberculosis
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
06
2022
accepted:
30
08
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Tuberculosis (TB) and AIDS are the leading causes of infectious diseases death worldwide. Here, we investigated the relationship between from single nucleotide polymorphisms (SNPs) of the NLRP3, CARD8, AIM2, CASP-1, IFI16, and IL-1β inflammasome genes, as well as the profiles of secreted proinflammatory cytokines (e.g., IL-1β, IL-18, IL-33, and IL-6) with the TB clinical profiles, TB-HIV coinfection, and IRIS onset. The individuals were divided into four groups: TB-HIV group (n=88; 11 of them with IRIS), HIV-1 group (n=20), TB group (n=24) and healthy volunteers (HC) group (n=10), and were followed up at INI/FIOCRUZ and HGNI (Rio de Janeiro/Brazil) from 2006 to 2016. Real-time PCR was used to determine the genotypes of the Single Nucleotide Polymorphism (SNPs), and ELISA was used to measure the plasma cytokine levels. Unconditional logistic regression models were used to perform risk estimations. A higher risk for extrapulmonary TB was associated with the TT genotype (aOR=6.76; P=0.026) in the NLRP3 rs4612666 Single Nucleotide Polymorphism (SNP) and the C-C-T-G-C haplotype (aOR=4.99; P= 0.017) in the NLRP3 variants. This same Single Nucleotide Polymorphism (SNP) was associated with lower risk against extrapulmonary TB when the carrier allele C (aOR=0.15; P=0.021) was present. Among those with HIV-1 infections, a higher risk for TB onset was associated with the GA genotype (aOR=5.5; P=0.044) in the IL1-β rs1143634 Single Nucleotide Polymorphism (SNP). In contrast, lower risk against TB onset was associated with the A-G haplotype (aOR=0.17; P= 0.026) in the CARD8 variants. Higher IL-6 and IL-33 levels were observed in individuals with TB. A higher risk for IRIS onset was associated with CD8 counts ≤ 500 cells/mm Our results depict the involvement of genetic polymorphisms of crucial innate immunity genes and proinflammatory cytokines in the clinical outcomes related to TB-HIV coinfection.
Sections du résumé
Background
Tuberculosis (TB) and AIDS are the leading causes of infectious diseases death worldwide. Here, we investigated the relationship between from single nucleotide polymorphisms (SNPs) of the NLRP3, CARD8, AIM2, CASP-1, IFI16, and IL-1β inflammasome genes, as well as the profiles of secreted proinflammatory cytokines (e.g., IL-1β, IL-18, IL-33, and IL-6) with the TB clinical profiles, TB-HIV coinfection, and IRIS onset.
Methods
The individuals were divided into four groups: TB-HIV group (n=88; 11 of them with IRIS), HIV-1 group (n=20), TB group (n=24) and healthy volunteers (HC) group (n=10), and were followed up at INI/FIOCRUZ and HGNI (Rio de Janeiro/Brazil) from 2006 to 2016. Real-time PCR was used to determine the genotypes of the Single Nucleotide Polymorphism (SNPs), and ELISA was used to measure the plasma cytokine levels. Unconditional logistic regression models were used to perform risk estimations.
Results
A higher risk for extrapulmonary TB was associated with the TT genotype (aOR=6.76; P=0.026) in the NLRP3 rs4612666 Single Nucleotide Polymorphism (SNP) and the C-C-T-G-C haplotype (aOR=4.99; P= 0.017) in the NLRP3 variants. This same Single Nucleotide Polymorphism (SNP) was associated with lower risk against extrapulmonary TB when the carrier allele C (aOR=0.15; P=0.021) was present. Among those with HIV-1 infections, a higher risk for TB onset was associated with the GA genotype (aOR=5.5; P=0.044) in the IL1-β rs1143634 Single Nucleotide Polymorphism (SNP). In contrast, lower risk against TB onset was associated with the A-G haplotype (aOR=0.17; P= 0.026) in the CARD8 variants. Higher IL-6 and IL-33 levels were observed in individuals with TB. A higher risk for IRIS onset was associated with CD8 counts ≤ 500 cells/mm
Conclusions
Our results depict the involvement of genetic polymorphisms of crucial innate immunity genes and proinflammatory cytokines in the clinical outcomes related to TB-HIV coinfection.
Identifiants
pubmed: 36204643
doi: 10.3389/fcimb.2022.962059
pmc: PMC9531132
doi:
Substances chimiques
CARD Signaling Adaptor Proteins
0
CARD8 protein, human
0
Inflammasomes
0
Interleukin-18
0
Interleukin-33
0
Interleukin-6
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
962059Informations de copyright
Copyright © 2022 de Sá, de Souza, Neira-Goulart, Ribeiro-Alves, Da Silva, Pilotto, Rolla, Giacoia-Gripp, de Oliveira Pinto, Scott-Algara, Morgado and Teixeira.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Rev. 2013 Jul;254(1):245-64
pubmed: 23772624
Blood. 2010 Nov 11;116(19):3818-27
pubmed: 20660788
Clin Infect Dis. 2006 Jun 1;42(11):1639-46
pubmed: 16652323
BMC Infect Dis. 2016 Sep 27;16(1):518
pubmed: 27677424
Clin Infect Dis. 2012 Oct;55(7):1004-11
pubmed: 22715179
J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):121-5
pubmed: 22227487
AIDS. 2015 Feb 20;29(4):421-31
pubmed: 25565499
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
J Immunol. 2012 Sep 15;189(6):2707-11
pubmed: 22904305
J Infect Dis. 2017 Mar 1;215(5):677-686
pubmed: 27932622
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
Springerplus. 2013 Dec 21;2:686
pubmed: 24455461
Eur Respir J. 2011 May;37(5):1248-59
pubmed: 20817712
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423-8
pubmed: 24226057
Arch Med Sci. 2021 Mar 18;18(1):1-10
pubmed: 35154519
Open Forum Infect Dis. 2018 Apr 11;5(5):ofy075
pubmed: 29732382
Clin Infect Dis. 2020 Aug 14;71(4):924-932
pubmed: 31751447
Oncol Lett. 2014 Jul;8(1):449-453
pubmed: 24959294
Tuberculosis (Edinb). 2015 Dec;95(6):817-821
pubmed: 26542219
J Genet. 2018 Mar;97(1):235-251
pubmed: 29666343
J Immunol. 2016 May 15;196(10):4052-63
pubmed: 27076678
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Front Immunol. 2017 Aug 04;8:930
pubmed: 28824650
Front Immunol. 2020 Nov 30;11:571593
pubmed: 33329534
AIDS. 2006 Jan 9;20(2):F1-7
pubmed: 16511406
AIDS. 2005 Mar 4;19(4):399-406
pubmed: 15750393
Int J Mol Med. 2012 Sep;30(3):697-702
pubmed: 22711073
Lancet Infect Dis. 2010 Apr;10(4):251-61
pubmed: 20334848
PLoS One. 2013 Jun 19;8(6):e66095
pubmed: 23840403
J Immunol. 2015 Feb 15;194(4):1748-54
pubmed: 25589068
PLoS One. 2016 Feb 22;11(2):e0147543
pubmed: 26901036
Int J Mol Sci. 2018 Sep 12;19(9):
pubmed: 30213101
Nat Commun. 2015 Sep 24;6:8451
pubmed: 26399326
Immunogenetics. 2017 Aug;69(8-9):489-498
pubmed: 28695282
AIDS Res Hum Retroviruses. 2019 Oct;35(10):948-959
pubmed: 31288555
AIDS. 2009 Jan 14;23(2):147-60
pubmed: 19098484
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):147-51
pubmed: 23507658
Front Immunol. 2019 Aug 13;10:1800
pubmed: 31456797
Am J Hum Genet. 2009 Aug;85(2):214-27
pubmed: 19664744
Arch Immunol Ther Exp (Warsz). 2019 Dec;67(6):367-373
pubmed: 31324923
Arthritis Res Ther. 2014 Feb 12;16(1):R52
pubmed: 24517500
Lancet Infect Dis. 2008 Aug;8(8):516-23
pubmed: 18652998
PLoS One. 2019 Jun 6;14(6):e0217014
pubmed: 31170171
PLoS One. 2015 Sep 11;10(9):e0137727
pubmed: 26359865
J Acquir Immune Defic Syndr. 2010 Jul;54(3):236-40
pubmed: 20502346
Curr HIV/AIDS Rep. 2014 Sep;11(3):223-32
pubmed: 24950732
BMC Infect Dis. 2020 Jan 20;20(1):59
pubmed: 31959123
Immunol Rev. 2015 May;265(1):6-21
pubmed: 25879280
AIDS. 2013 Oct 23;27(16):2577-86
pubmed: 24096631
Exp Ther Med. 2021 Oct;22(4):1110
pubmed: 34504564
AIDS. 2004 Aug 20;18(12):1615-27
pubmed: 15280772
J Int Med Res. 2021 Aug;49(8):3000605211036832
pubmed: 34463584
PLoS One. 2016 Sep 19;11(9):e0163298
pubmed: 27643598
Braz J Infect Dis. 2007 Oct;11(5):462-5
pubmed: 17962870
Front Immunol. 2021 Oct 07;12:757843
pubmed: 34691079
Biology (Basel). 2021 Jun 27;10(7):
pubmed: 34199122
BMC Infect Dis. 2017 Sep 6;17(1):606
pubmed: 28874142
J Immunol Res. 2021 Sep 20;2021:1487287
pubmed: 34595244
Front Immunol. 2018 Dec 04;9:2850
pubmed: 30564243
Medicine (Baltimore). 2018 Jul;97(30):e11645
pubmed: 30045312
Sci Rep. 2020 Jun 23;10(1):10184
pubmed: 32576967
Sci Rep. 2017 Jan 27;7:41240
pubmed: 28128217
J Infect Dis. 2011 Jun 1;203(11):1637-46
pubmed: 21592994
Cell. 2016 May 5;165(4):792-800
pubmed: 27153493
PLoS Genet. 2009 Dec;5(12):e1000791
pubmed: 20041166
Int Immunol. 2012 Oct;24(10):637-44
pubmed: 22695634
Pediatr Infect Dis J. 2016 Jul;35(7):802-4
pubmed: 27097352